Product Description
recombinant human GDF-5 coated onto beta-tricalcium phosphate
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Scil Technology
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Alveolar Bone Loss|Other
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Scil-MD05-C02 | P2 |
Unknown status |
Alveolar Bone Loss |
2008-10-01 |
|
| Scil-MD05-C02 | P2 |
Completed |
Unknown |
2008-08-26 |
|
| Sinus Lift Study | P2 |
Completed |
Unknown |
2008-03-04 |
|
| Scil-MD05-C01 | P2 |
Unknown status |
Other |
2007-12-01 |